Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 10 (April 1), 2008: pp. 1619-1625
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.12.2051

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pedrazzoli, P.
Right arrow Articles by Siena, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pedrazzoli, P.
Right arrow Articles by Siena, S.
Related Articles
Right arrowRelated Article
Right arrowRelated Editorial
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa

Paolo Pedrazzoli, Antonio Farris, Salvatore Del Prete, Filomena Del Gaizo, Daris Ferrari, Clara Bianchessi, Giuseppe Colucci, Alberto Desogus, Teresa Gamucci, Alessandro Pappalardo, Giuseppe Fornarini, Paola Pozzi, Alessandra Fabi, Roberto Labianca, Francesco Di Costanzo, Simona Secondino, Enrico Crucitta, Federica Apolloni, Antonio Del Santo, Salvatore Siena

From the Oncologia Medica Falck, Ospedale Niguarda Ca’ Granda; Oncologia Medica, Polo Universitario Ospedale San Paolo; Dompé Biotec, Milano; Clinica Medica Generale e Terapia Medica, Università degli Studi di Sassari; Ospedale S. Giovanni di Dio, Frattaminore (NA); Ospedale San Giuseppe Moscati, Avellino; Medicina Oncologica, Ospedale Maggiore di Crema; IRCCS Ospedale Oncologico, Bari; Ospedale Oncologico A. Businco, Cagliari; Ospedale SS. Trinità, Soro (FR), Oncologia Medica, Ospedale O. Morgagni, Catania; Oncologia Medica, Ospedale San Martino, Genova; Oncologia Medica, Ospedale Civile di Vimercate, Milano; Istituto Regina Elena, Roma; Oncologia Medica, Ospedali Riuniti di Bergamo; and Oncologia Medica, Ospedale Careggi, Firenze, Italy

Corresponding author: Paolo Pedrazzoli, MD, Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca’ Granda, Piazza Ospedale Maggiore 20162, Milano, Italy; e-mail: paolo.pedrazzoli{at}ospedaleniguarda.it

Purpose Unresponsiveness to erythropoiesis-stimulating agents, occurring in 30% to 50% of patients, is a major limitation to the treatment of chemotherapy-related anemia. We have prospectively evaluated whether intravenous iron can increase the proportion of patients with chemotherapy-related anemia who respond to darbepoetin.

Patients and Methods Between December 2004 and February 2006, 149 patients with lung, gynecologic, breast, and colorectal cancers and ≥ 12 weeks of planned chemotherapy were enrolled from 33 institutions. Patients were required to have hemoglobin ≤ 11 g/L and no absolute or functional iron deficiency. All patients received darbepoetin 150 µg subcutaneously once weekly for 12 weeks and were randomly assigned to sodium ferric gluconate 125 mg intravenously (IV) weekly for the first 6 weeks (n = 73) or no iron (n = 76). Primary end point of the study was the percentage of patients achieving hematopoietic response (hemoglobin ≥ 12 g/dL or ≥ 2 g/dL increase).

Results Hematopoietic response by intention-to-treat analysis was 76.7% (95%CI, 65.4% to 85.8%) in the darbepoetin/iron group and 61.8% (95%CI, 50.0% to 72.7%) in the darbepoetin group (P = .0495). Among patients fulfilling eligibility criteria and having received at least four darbepoetin administrations, hematopoietic responses in the darbepoetin/iron group (n = 53) and in the darbepoetin-only group (n = 50) were 92.5% (95% CI, 81.8% to 97.9%) and 70% (95% CI, 55.4% to 82.1%), respectively (P = .0033). Increase of hemoglobin during treatment period showed a time profile favoring darbepoetin/iron with statistically significant effect from week 5 on. The safety profile was comparable in the two arms.

Conclusion In patients with chemotherapy-related anemia and no iron deficiency, IV iron supplementation significantly reduces treatment failures to darbepoetin without additional toxicity.

Supported by Dompé Biotec. S.S. is recipient of a research contract supported in part by Oncologia Ca’ Granda ONLUS Fondazione.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

  • Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia
    Laurent Bastit, An Vandebroek, Sevilay Altintas, Bernd Gaede, Tamás Pintér, Tamas S. Suto, Tony W. Mossman, Kay E. Smith, and Johan F. Vansteenkiste
    JCO 2008 26: 1611-1618 [Abstract] [Full Text]

Related Editorial

  • Should Intravenous Iron Be the Standard of Care in Oncology?
    Michael Auerbach
    JCO 2008 26: 1579-1581 [Full Text]


This article has been cited by other articles:


Home page
Journal of Pharmacy PracticeHome page
S. B. Silverstein, J. A. Gilreath, and G. M. Rodgers
Intravenous Iron Therapy: A Summary of Treatment Options and Review of Guidelines
Journal of Pharmacy Practice, December 1, 2008; 21(6): 431 - 443.
[Abstract] [PDF]


Home page
ASH Education BookHome page
J. W. Adamson
The Anemia of Inflammation/Malignancy: Mechanisms and Management
Hematology, January 1, 2008; 2008(1): 159 - 165.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
Appendix: Color Figures
Hematology, January 1, 2008; 2008(1): 491 - 506.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online